Efficacy of etanercept in an integrated multistudy database of patients with psoriasis

Journal of the American Academy of Dermatology

Volumn 54, Issue 3 SUPPL. 2, 2006, Pages

  Gordon, Kenneth ^a,e   Korman, Neil ^b   Frankel, Ellen ^c   Wang, Huei ^d   Jahreis, Angelika ^d   Zitnik, Ralph ^d   Chang, Ting ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Clinical Partners   (United States)

^d AMGEN INC   (United States)

^e Division of Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA ANALYSIS; DERMATOLOGY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION SIZE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RATING SCALE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 32644441215     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.11.1088     Document Type: Article

References (35)

1. A.B. Gottlieb Psoriasis. Immunopathology and immunomodulation Dermatol Clin 19 2001 649 657 viii
2. J.G. Krueger, J.F. Krane, D.M. Carter, and A.B. Gottlieb Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis J Invest Dermatol 94 1990 135S 140S
3. A.Y. Finlay, and E.C. Coles The effect of severe psoriasis on the quality of life of 369 patients Br J Dermatol 132 1995 236 244
4. G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, and T. Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
5. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr., and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
6. S.R. Rapp, C.A. Cottrell, and M.R. Leary Social coping strategies associated with quality of life decrements among psoriasis patients Br J Dermatol 145 2001 610 616
7. J. Choi, and J.Y. Koo Quality of life issues in psoriasis J Am Acad Dermatol 49 2003 S57 S61
8. J.G. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23
9. T.S. Kupper Immunologic targets in psoriasis N Engl J Med 349 2003 1987 1990
10. C. Bonifati, and F. Ameglio Cytokines in psoriasis Int J Dermatol 38 1999 241 251
11. D.M. Ashcroft, P.A. Li Wan, and C.E. Griffiths Therapeutic strategies for psoriasis J Clin Pharm Ther 25 2000 1 10
12. S. Feldman Advances in psoriasis treatment Dermatol Online J 6 2000 4
13. M. Lebwohl Psoriasis Lancet 361 2003 1197 1204
14. G.G. Krueger, K.A. Papp, D.B. Stough, K.H. Loven, W.P. Gulliver, and C.N. Ellis A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833
15. K.B. Gordon, K.A. Papp, T.K. Hamilton, P.A. Walicke, W. Dummer, and N. Li Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 2003 3073 3080
16. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
17. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 2000 385 390
18. L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, and K.J. Bulpitt Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 1999 478 486
19. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, and R.I. Fox A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253 259
20. J. Brandt, A. Khariouzov, J. Listing, H. Haibel, H. Sorensen, and L. Grassnickel Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis Rheum 48 2003 1667 1675
21. J.C. Davis Jr., D. van der Heijde, J. Braun, M. Dougados, J. Cush, and D.O. Clegg Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 2003 3230 3236
22. J.D. Gorman, K.E. Sack, and J.C. Davis Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N Engl J Med 346 2002 1349 1356
23. D.J. Lovell, E.H. Giannini, A. Reiff, O.Y. Jones, R. Schneider, and J.C. Olson Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial Arthritis Rheum 48 2003 218 226
24. R.A. Russo, M.M. Katsicas, and M. Zelazko Etanercept in systemic juvenile idiopathic arthritis Clin Exp Rheumatol 20 2002 723 726
25. D.J. Lovell, E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, and J.J. Nocton Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group N Engl J Med 342 2000 763 769
26. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
27. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
28. K. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E.M. Griffiths, and A.M. Nakanishi A global phase 3 study of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br. J Dermatol 152 2004 1304 1312
29. ® (etanercept) Full prescribing information [package insert] 2005 Immunex Corp Thousand Oaks (Calif)
30. T. Fredriksson, and U. Pettersson Severe psoriasis - oral therapy with a new retinoid Dermatologica 157 1978 238 244
31. V. Lewis, and A.Y. Finlay 10 years experience of the Dermatology Life Quality Index (DLQI) J Investig Dermatol Symp Proc 9 2004 169 180
32. M.A. Sprangers, and N.K. Aaronson The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review J Clin Epidemiol 45 1992 743 760
33. A. Jayaprakasam, A. Darvay, G. Osborne, and D. McGibbon Comparison of assessments of severity and quality of life in cutaneous disease Clin Exp Dermatol 27 2002 306 308
34. G.B. Jemec, and H.C. Wulf Patient-physician consensus on quality of life in dermatology Clin Exp Dermatol 21 1996 177 179
35. C.R. Touw, L. Hakkaart-Van Roijen, P. Verboom, C. Paul, F.F. Rutten, and A.Y. Finlay Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin Br J Dermatol 144 2001 967 972